MX377244B - Formulacion arn para inmunoterapia. - Google Patents

Formulacion arn para inmunoterapia.

Info

Publication number
MX377244B
MX377244B MX2014011466A MX2014011466A MX377244B MX 377244 B MX377244 B MX 377244B MX 2014011466 A MX2014011466 A MX 2014011466A MX 2014011466 A MX2014011466 A MX 2014011466A MX 377244 B MX377244 B MX 377244B
Authority
MX
Mexico
Prior art keywords
immunotherapy
rna
systemic administration
present
rna formulation
Prior art date
Application number
MX2014011466A
Other languages
English (en)
Other versions
MX2014011466A (es
Inventor
Daniel Fritz
Heinrich Haas
Kerstin Reuter
Lena Mareen Kranz
Martin Meng
Mustafa Diken
Sebastian Kreiter
Ugur Sahin
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of MX2014011466A publication Critical patent/MX2014011466A/es
Publication of MX377244B publication Critical patent/MX377244B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a el campo de inmunoterapia, en particular la inmunoterapia de tumores. La presente invención proporciona formulaciones farmacéuticas para suministrar ARN a células presentadoras de antígenos tales como las células dendríticas (DC) en el bazo después de una administración sistémica. En particular, las formulaciones descritas en la presente permiten inducir una respuesta inmunitaria después de la administración sistémica de un ARN antígeno-codificante.
MX2014011466A 2012-03-26 2013-03-25 Formulacion arn para inmunoterapia. MX377244B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/001319 WO2013143555A1 (en) 2012-03-26 2012-03-26 Rna formulation for immunotherapy
PCT/EP2013/000902 WO2013143683A1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy

Publications (2)

Publication Number Publication Date
MX2014011466A MX2014011466A (es) 2015-06-03
MX377244B true MX377244B (es) 2025-03-07

Family

ID=48044720

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014011466A MX377244B (es) 2012-03-26 2013-03-25 Formulacion arn para inmunoterapia.
MX2020011696A MX2020011696A (es) 2012-03-26 2014-09-24 Formulacion arn para inmunoterapia.
MX2020011781A MX2020011781A (es) 2012-03-26 2014-09-24 Formulacion arn para inmunoterapia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020011696A MX2020011696A (es) 2012-03-26 2014-09-24 Formulacion arn para inmunoterapia.
MX2020011781A MX2020011781A (es) 2012-03-26 2014-09-24 Formulacion arn para inmunoterapia.

Country Status (20)

Country Link
US (3) US10485884B2 (es)
JP (4) JP6279545B2 (es)
CN (2) CN109331176B (es)
AU (3) AU2013242512B2 (es)
BR (1) BR112014022562A8 (es)
CA (2) CA3088428C (es)
DK (2) DK3777840T3 (es)
ES (3) ES3030907T3 (es)
HR (1) HRP20201578T1 (es)
HU (2) HUE044594T2 (es)
LT (2) LT2830593T (es)
MX (3) MX377244B (es)
NZ (1) NZ628328A (es)
PL (1) PL3777840T3 (es)
PT (2) PT3427723T (es)
RS (1) RS61002B1 (es)
SI (1) SI3427723T1 (es)
SM (1) SMT202000603T1 (es)
TR (1) TR201904758T4 (es)
WO (2) WO2013143555A1 (es)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3998064A1 (en) 2011-06-08 2022-05-18 Translate Bio, Inc. Cleavable lipids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
EP3988537A1 (en) 2011-12-07 2022-04-27 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
CN105073135A (zh) 2013-02-22 2015-11-18 库瑞瓦格有限责任公司 疫苗接种和抑制pd-1途径的组合
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015138357A2 (en) 2014-03-09 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of otc deficency
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
CN107592807B (zh) 2015-02-26 2022-04-15 Sio2医药产品公司 具有耐划伤且抗静电的涂层的环烯烃聚合物容器
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
WO2016170176A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
EP3288594B1 (en) 2015-04-27 2022-06-29 The Trustees of The University of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
US11090332B2 (en) * 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
CN114085198A (zh) 2015-06-29 2022-02-25 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
WO2017015457A1 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
CN108351350B (zh) 2015-08-25 2022-02-18 杜克大学 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
BR112018008090A2 (pt) * 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
CA3003090A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
CA3003103A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
EP3383418B1 (en) * 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3458083B1 (en) 2016-05-18 2022-11-02 ModernaTX, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
IL317855A (en) * 2016-10-26 2025-02-01 Acuitas Therapeutics Inc mRNA vaccines with lipid nanoparticles
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP7738979B2 (ja) * 2016-11-10 2025-09-16 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
FI3596041T3 (fi) 2017-03-15 2023-01-31 Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
CA3057768A1 (en) * 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
EP3681993A1 (en) 2017-09-13 2020-07-22 BioNTech RNA Pharmaceuticals GmbH Rna replicon for reprogramming somatic cells
AU2018333530B2 (en) 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
EP3858333B1 (en) * 2017-10-20 2025-11-26 BioNTech SE Preparation and storage of liposomal rna formulations suitable for therapy
MX2020008394A (es) * 2018-02-12 2020-09-21 Biontech Rna Pharmaceuticals Gmbh Tratamiento que usa arn que codifica citoquinas.
EP3765477A1 (en) 2018-03-15 2021-01-20 BioNTech RNA Pharmaceuticals GmbH 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
JP7550745B2 (ja) 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
WO2020020444A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
EP3836964A1 (en) * 2018-08-15 2021-06-23 University of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
CN112702994A (zh) * 2018-09-18 2021-04-23 根特大学 治疗性纳米颗粒及其使用方法
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP4613367A1 (en) 2018-09-21 2025-09-10 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
WO2020144295A1 (en) 2019-01-10 2020-07-16 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
MX2021009506A (es) 2019-02-08 2021-09-08 Biontech Cell & Gene Therapies Gmbh Tratamiento que implica celulas t modificadas con car y citoquinas.
LT3920939T (lt) 2019-02-08 2025-01-10 Biontech Cell & Gene Therapies Gmbh Ląstelės su modifikuotu chimeriniu antigeno receptoriumi, skirtos cldn6 ekspresuojančio vėžio gydymui
AU2020233995A1 (en) 2019-03-12 2021-09-23 BioNTech SE Therapeutic RNA for prostate cancer
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CA3133414A1 (en) 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
US12558407B2 (en) 2019-05-02 2026-02-24 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
KR20220010500A (ko) * 2019-05-20 2022-01-25 비온테크 에스이 난소암 치료용 rna
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
WO2021008708A1 (en) * 2019-07-18 2021-01-21 Biontech Rna Pharmaceuticals Gmbh Method for determining at least one parameter of a sample composition comprising nucleic acid, such as rna, and optionally particles
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
WO2021085696A1 (ko) * 2019-11-01 2021-05-06 한국과학기술원 작은 지질 나노 입자 및 이를 포함하는 암 백신
JP7660568B2 (ja) * 2019-11-07 2025-04-11 サムヤン ホールディングス コーポレイション 免疫誘導用ポリマーナノ粒子組成物及びその製造方法
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
CA3171370A1 (en) 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
MX2022012683A (es) 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
US11547673B1 (en) 2020-04-22 2023-01-10 BioNTech SE Coronavirus vaccine
EP4162034A1 (en) 2020-06-04 2023-04-12 BioNTech SE Rna replicon for versatile and efficient gene expression
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
DK4182297T3 (da) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc Kationiske lipider til brug i lipid-nanopartikler
JP2023534283A (ja) 2020-07-17 2023-08-08 ジェネンテック， インコーポレイテッド ペプチドの結合、提示及び免疫原性を予測するための注意ベースのニューラルネットワーク
MX2023002670A (es) 2020-09-08 2023-05-08 Genentech Inc Sistemas y procedimientos para producir composiciones farmaceuticas usando bombas peristalticas y amortiguadores.
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
MX2023005386A (es) 2020-11-11 2023-05-23 BioNTech SE Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
EP4008785A1 (en) 2020-12-03 2022-06-08 Justus-Liebig-Universität Gießen Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
IT202100003470A1 (it) 2021-02-16 2022-08-16 Fond Toscana Life Sciences Vaccines against sars-cov-2
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
MX2023010461A (es) * 2021-03-08 2023-09-14 Eyegene Inc Composicion para la entrega in vivo de arn y metodo de preparacion para la misma.
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
AU2022260466A1 (en) 2021-04-20 2023-11-02 BioNTech SE Virus vaccine
WO2022235853A1 (en) 2021-05-04 2022-11-10 BioNTech SE Immunogen selection
CA3221330A1 (en) 2021-06-08 2022-12-15 Biontech Cell & Gene Therapies Gmbh Agents and methods for activation and targeting of immune effector cells
TW202320842A (zh) 2021-07-29 2023-06-01 德商拜恩技術股份公司 用於治療黑色素瘤之組合物及方法
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333803A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性ｒｎａ（一）
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023061550A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
US20240366754A1 (en) 2021-10-15 2024-11-07 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
JP2024539089A (ja) 2021-10-18 2024-10-28 バイオエヌテック エスエー 修飾複製可能ｒｎａの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用
CN118103516A (zh) 2021-10-18 2024-05-28 生物技术欧洲股份公司 修饰的可复制rna和相关组合物及其用途
CN118900696A (zh) 2021-10-19 2024-11-05 科学医疗有限责任公司 雄性避孕
US20250222096A1 (en) 2021-10-21 2025-07-10 BioNTech SE Coronavirus vaccine
JP2024540948A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア 異なる投与のｒｎａを投与するための組成物
JP2024541993A (ja) 2021-10-28 2024-11-13 ビオンテック・ソシエタス・エウロパエア Ｒｎａコンストラクト及びその使用
FR3129833B1 (fr) 2021-12-03 2024-09-06 Univ Claude Bernard Lyon Nanoparticules pour la liberation d’acides nucleiques
JP2024545154A (ja) 2021-12-09 2024-12-05 ビオンテック・ソシエタス・エウロパエア Ｃｌｄｎ６発現がんの処置のためのキメラ抗原受容体改変細胞
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
US20250345416A1 (en) 2022-01-27 2025-11-13 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
US20260041769A1 (en) 2022-02-02 2026-02-12 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
EP4472672A1 (en) 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery to cells
EP4482962A1 (en) 2022-02-24 2025-01-01 IO Biotech ApS Nucleotide delivery of cancer therapy
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
EP4544051A2 (en) 2022-06-24 2025-04-30 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
CN115300641B (zh) * 2022-08-01 2025-03-04 深圳市人民医院 一种靶向树突状细胞促进抗原溶酶体逃逸激活免疫系统的抗原递送载体其制备方法与应用
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
EP4565266A1 (en) 2022-08-03 2025-06-11 Nanoramic, Inc. Rna for preventing or treating tuberculosis
JP2025532591A (ja) 2022-09-15 2025-10-01 ビオンテック・ソシエタス・エウロパエア ｍｉＲＮＡを有するトランス増幅ＲＮＡベクターを含むシステムおよび組成物
AU2023347387A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
AU2023347390A1 (en) 2022-09-23 2025-04-10 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
JP2025539935A (ja) 2022-11-15 2025-12-10 ジェネンテック， インコーポレイテッド ペプチド治療薬のための多様な候補ペプチドの選択
AU2023408612A1 (en) 2022-12-20 2025-07-03 BioNTech SE Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024153324A1 (en) 2023-01-18 2024-07-25 BioNTech SE Rna formulations for pharmaceutical use
TW202434263A (zh) 2023-01-27 2024-09-01 德商拜恩技術股份公司 用於遞送單純疱疹病毒醣蛋白ｃ、醣蛋白ｄ、及醣蛋白ｅ抗原之醫藥組成物及相關方法
WO2024160828A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
WO2024180363A1 (en) 2023-02-28 2024-09-06 BioNTech SE Linker sequence potency assays for multiple coding nucleic acids
JP2026508330A (ja) 2023-02-28 2026-03-10 バイオンテック・エスイー 多重コーディング核酸のリンカー配列効力アッセイ
KR20250169566A (ko) 2023-04-14 2025-12-03 바이오엔테크 에스이 Hiv 백신
WO2024216214A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
EP4694919A1 (en) 2023-04-14 2026-02-18 BioNTech SE Rna for preventing or treating tuberculosis
WO2024213776A1 (en) 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
EP4704883A1 (en) 2023-05-01 2026-03-11 Yale University Antigen-specific physiologic dendritic cells for therapy
WO2024227807A1 (en) 2023-05-01 2024-11-07 Yale University Antigen-specific physiologic dendritic cells for vaccination
AU2024265158A1 (en) 2023-05-03 2025-11-06 BioNTech SE Optimized csp variants and related methods
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
KR20260011140A (ko) 2023-05-15 2026-01-22 제넨테크, 인크. 종양 내 돌연변이를 페이징하기 위한 시스템 및 방법
CN119997938A (zh) * 2023-06-05 2025-05-13 安徽医科大学第一附属医院 肺靶向纳米胶束、制备方法及应用
WO2025021277A1 (en) * 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025024335A2 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
AU2024299365A1 (en) 2023-07-24 2026-01-08 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
AU2024316307A1 (en) 2023-08-03 2026-02-26 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
AU2024328030A1 (en) 2023-08-24 2026-03-12 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025061863A1 (en) 2023-09-20 2025-03-27 BioNTech SE Method
WO2025083147A1 (en) 2023-10-17 2025-04-24 Transimmune Ag Methods for analyzing immune responses and antigen profiling
TW202539697A (zh) 2023-11-15 2025-10-16 德商拜恩技術股份公司 冠狀病毒疫苗
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155607A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025186660A1 (en) 2024-03-05 2025-09-12 Fondazione Toscana Life Sciences Mutated spike proteins as vaccines against sars-cov-2
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025209797A1 (en) 2024-04-03 2025-10-09 BioNTech SE Interleukin 18 receptor agents for specific activation of immune effector cells
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
CN118001254B (zh) 2024-04-09 2024-07-26 北京悦康科创医药科技股份有限公司 靶向抗原呈递细胞的脂质组合物及其应用
WO2025223684A1 (en) 2024-04-23 2025-10-30 BioNTech SE Methods and compositions for stimulating immune response
WO2025224684A1 (en) 2024-04-24 2025-10-30 BioNTech SE Compositions and methods for producing engineered immune cells
WO2025264662A1 (en) 2024-06-18 2025-12-26 BioNTech SE Compositions and methods for treatment of melanoma
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026041793A1 (en) 2024-08-23 2026-02-26 BioNTech SE Chimeric proteins comprising non-human protein domains for enhancing antigenicity
WO2026047153A1 (en) 2024-08-28 2026-03-05 BioNTech SE Potency assay for multiple coding nucleic acids
WO2026047148A1 (en) 2024-08-29 2026-03-05 BioNTech SE Minimal polypeptide-encoding rnas

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
CN1138533C (zh) 1996-09-13 2004-02-18 利普森有限公司 脂质体
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
TR200001253T2 (tr) 1997-11-06 2000-11-21 Roche Diagnostics Gmbh Tümöre özel antijenler
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
AU6289699A (en) 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
EP1178785B1 (en) 1999-05-06 2008-12-24 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
EP1261704B1 (en) 1999-11-30 2009-07-01 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
MXPA02006554A (es) 1999-12-28 2003-09-22 Epimmune Inc Minigenes optimizados y peptidos codificados por los mismos.
WO2001093902A2 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
ES2329461T3 (es) 2002-06-13 2009-11-26 Merck Patent Gmbh Procedimiento para la identificacion de alo-antigenos y su empleo para la terapia del cancer y en el transplante.
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
JP4545151B2 (ja) * 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
AU2004283464B8 (en) 2003-10-15 2011-04-14 Syncore Biotechnology Co., Ltd Method of administering cationic liposomes comprising an active drug
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
JP2008526764A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 免疫応答の誘導におけるｃｄ４＋細胞の回避方法
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
CA2651796A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US20100092572A1 (en) 2007-01-29 2010-04-15 Peter Kaeuper Chitosan-based colloidal particles for rna delivery
EP1955695A1 (en) * 2007-02-06 2008-08-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanocapsules of lipophilic complexes of nucleic acids
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
RU2010133547A (ru) * 2008-01-11 2012-02-20 Дзе Юниверсити Оф Токио (Jp) Анти-cldn антитела
MX344330B (es) 2008-03-24 2016-12-13 4Sc Ag Imidazoquinolinas substituidas novedosas.
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
PL215513B1 (pl) * 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010014895A2 (en) 2008-07-31 2010-02-04 Enzon Pharmaceuticals, Inc. Nanoparticle compositions for nucleic acids delivery system
JP5382682B2 (ja) 2008-09-01 2014-01-08 国立大学法人 長崎大学 薬物送達複合体
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP5777519B2 (ja) * 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
BR112012002291A2 (pt) 2009-07-31 2016-11-29 Ethris Gmbh "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos"
CA2783372C (en) * 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
RS54489B1 (sr) * 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
HRP20221048T1 (hr) * 2010-08-31 2022-11-11 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
CN102133404B (zh) 2011-03-23 2013-01-16 成都诺恩生物科技有限公司 一种肿瘤靶向治疗药物载体、其制备方法及其应用
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
US20140141070A1 (en) * 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
CN103781470A (zh) * 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2817322B1 (en) 2012-02-20 2016-04-20 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
DK3427723T3 (da) 2012-03-26 2020-10-12 Biontech Rna Pharmaceuticals Gmbh Rna-formulering til immunterapi
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
EP3511425A1 (en) 2012-07-12 2019-07-17 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
MX363017B (es) 2012-11-01 2019-03-04 Factor Bioscience Inc Métodos y productos para la expresión de proteínas en células.
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
EP3049065A1 (en) 2013-09-26 2016-08-03 BioNTech AG Particles comprising a shell with rna
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2938700A1 (en) 2014-02-05 2015-08-13 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
KR102580696B1 (ko) 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
EP3858333B1 (en) * 2017-10-20 2025-11-26 BioNTech SE Preparation and storage of liposomal rna formulations suitable for therapy

Also Published As

Publication number Publication date
SMT202000603T1 (it) 2021-01-05
JP7096282B2 (ja) 2022-07-05
MX2020011781A (es) 2020-11-24
CA3088428A1 (en) 2013-10-03
ES3030907T3 (en) 2025-07-02
CA2864253C (en) 2020-09-29
AU2013242512A1 (en) 2014-08-28
AU2017279565A1 (en) 2018-01-18
US11559587B2 (en) 2023-01-24
HRP20201578T1 (hr) 2021-03-05
PT3427723T (pt) 2020-10-12
AU2013242512A8 (en) 2014-09-18
JP6279545B2 (ja) 2018-02-14
RS61002B1 (sr) 2020-11-30
US20150086612A1 (en) 2015-03-26
BR112014022562A2 (es) 2017-08-22
CA3088428C (en) 2023-08-01
CN109331176B (zh) 2022-12-02
AU2020202152B2 (en) 2022-12-22
JP2018024704A (ja) 2018-02-15
HUE044594T2 (hu) 2019-11-28
WO2013143683A1 (en) 2013-10-03
NZ628328A (en) 2016-05-27
JP2015514076A (ja) 2015-05-18
AU2020202152A1 (en) 2020-04-16
DK3777840T3 (da) 2025-06-02
DK2830593T3 (en) 2019-04-23
LT3427723T (lt) 2020-12-28
CA2864253A1 (en) 2013-10-03
JP6596478B2 (ja) 2019-10-23
AU2013242512B2 (en) 2018-01-18
MX2020011696A (es) 2020-12-10
WO2013143683A8 (en) 2013-12-12
AU2017279565B2 (en) 2020-01-30
ES2719480T3 (es) 2019-07-10
PL3777840T3 (pl) 2025-06-09
BR112014022562A8 (pt) 2022-10-11
JP2020114865A (ja) 2020-07-30
US20200085974A1 (en) 2020-03-19
CN104302276A (zh) 2015-01-21
PT2830593T (pt) 2019-05-06
JP2019031571A (ja) 2019-02-28
JP6832904B2 (ja) 2021-02-24
LT2830593T (lt) 2019-06-25
HUE052485T2 (hu) 2021-05-28
US20230226217A1 (en) 2023-07-20
CN109331176A (zh) 2019-02-15
US10485884B2 (en) 2019-11-26
HK1202060A1 (en) 2015-09-18
TR201904758T4 (tr) 2019-04-22
ES2823239T3 (es) 2021-05-06
WO2013143555A1 (en) 2013-10-03
SI3427723T1 (sl) 2020-12-31
MX2014011466A (es) 2015-06-03

Similar Documents

Publication Publication Date Title
MX377244B (es) Formulacion arn para inmunoterapia.
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
MX392812B (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
MY197851A (en) Antibody formulations
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
MX389568B (es) Péptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cáncer de pulmón, que incluye cáncer de pulmón de células no pequeñas (nsclc)
EA201790239A1 (ru) Молекула-носитель для антигенов
WO2016142783A3 (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201391597A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
MX351453B (es) Composiciones de liberacion sostenida a base de lipidos anfipaticos.
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
MX343410B (es) Emulsiones cationicas de agua en aceite.
MX363307B (es) Plataformas para suministro de antigenos.
WO2013054199A3 (en) Cmv antigens and uses thereof
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
CY1123453T1 (el) Σκευασμα rna για ανοσοθεραπεια
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIONTECH SE

GB Transfer or rights

Owner name: BIONTECH SE

FG Grant or registration
PD Change of proprietorship

Owner name: BIONTECH SE